Physician profile
Jessie Kim
NPI 1356924195
$5,679.43
in general payments reported to CMS, 2019-2025
24 companies · $3,526 in 2025
The $3,526 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $113 · 2024: $2,041 · 2025: $3,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,606 · Education: $66.99 · Travel and Lodging: $6.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,606.41 |
| Education | $66.99 |
| Travel and Lodging | $6.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.28 | 2023-2025 | |
| Journey Medical Corporation | $525.88 | 2024-2025 | Emrosi |
| Genzyme Corporation | $506.47 | 2023-2025 | |
| Lilly USA, LLC | $465.44 | 2023-2025 | Ebglyss, Taltz, Zepbound |
| Galderma Laboratories, L.P. | $465.42 | 2023-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $353.60 | 2024-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $345.19 | 2024-2025 | |
| Incyte Corporation | $306.77 | 2023-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $299.45 | 2024-2025 | Tremfya |
| Ucb, INC. | $246.80 | 2024-2025 | Bimzelx |
| Pfizer INC. | $232.03 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $160.13 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $157.40 | 2023-2025 | |
| Lnhc, INC | $147.03 | 2025 | Zelsuvmi |
| Organon LLC | $146.24 | 2025 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $124.98 | 2024 | Affinity |
| Amgen INC. | $111.35 | 2024-2025 | Otezla, Otezla |
| Strata Skin Sciences, INC. | $78.60 | 2025 | Xtrac |
| Leo Pharma INC. | $43.85 | 2025 | Anzupgo |
| Dermavant Sciences, INC. | $28.36 | 2024 | Vtama |
| Biofrontera INC. | $25.74 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Regeneron Healthcare Solutions, INC. | $22.29 | 2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.08 | 2025 | Jublia, Siliq, Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.05 | 2024 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessie Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.